Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Schaub C, et al. Among authors: vatter h. J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28. J Cancer Res Clin Oncol. 2018. PMID: 29808316 Clinical Trial.
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: vatter h. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.
Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, Güresir E, Joseph K, Pietsch T, Schuss P, Herrlinger U, Westhoff MA, Vatter H, Waha A, Schneider M. Potthoff AL, et al. Among authors: vatter h. Cancers (Basel). 2019 Jun 20;11(6):858. doi: 10.3390/cancers11060858. Cancers (Basel). 2019. PMID: 31226836 Free PMC article.
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Kebir S, et al. Among authors: vatter h. J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19. J Neurooncol. 2019. PMID: 31325144 Clinical Trial.
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center.
Budde MK, Kuhn W, Keyver-Paik MD, Bootz F, Kalff JC, Müller SC, Bieber T, Brossart P, Vatter H, Herrlinger U, Wirtz DC, Schild HH, Kristiansen G, Pietsch T, Aretz S, Geiser F, Radbruch L, Reich RH, Strassburg CP, Skowasch D, Essler M, Ernstmann N, Landsberg J, Funke B, Schmidt-Wolf IGH. Budde MK, et al. Among authors: vatter h. BMC Cancer. 2019 Oct 30;19(1):1024. doi: 10.1186/s12885-019-6241-9. BMC Cancer. 2019. PMID: 31666035 Free PMC article.
Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol.
Golla H, Nettekoven C, Bausewein C, Tonn JC, Thon N, Feddersen B, Schnell O, Böhlke C, Becker G, Rolke R, Clusmann H, Herrlinger U, Radbruch L, Vatter H, Güresir E, Stock S, Müller D, Civello D, Papachristou I, Hellmich M, Hamacher S, Voltz R, Goldbrunner R; EPCOG study group. Golla H, et al. Among authors: vatter h. BMJ Open. 2020 Jan 7;10(1):e034378. doi: 10.1136/bmjopen-2019-034378. BMJ Open. 2020. PMID: 31915175 Free PMC article.
Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome.
Freytag M, Herrlinger U, Hauser S, Bauernfeind FG, Gonzalez-Carmona MA, Landsberg J, Buermann J, Vatter H, Holderried T, Send T, Schumacher M, Koscielny A, Feldmann G, Heine M, Skowasch D, Schäfer N, Funke B, Neumann M, Schmidt-Wolf IGH. Freytag M, et al. Among authors: vatter h. BMC Cancer. 2020 Apr 28;20(1):355. doi: 10.1186/s12885-020-06809-1. BMC Cancer. 2020. PMID: 32345242 Free PMC article.
Impact of initial midline shift in glioblastoma on survival.
Wach J, Hamed M, Schuss P, Güresir E, Herrlinger U, Vatter H, Schneider M. Wach J, et al. Among authors: vatter h. Neurosurg Rev. 2021 Jun;44(3):1401-1409. doi: 10.1007/s10143-020-01328-w. Epub 2020 Jun 4. Neurosurg Rev. 2021. PMID: 32494988
307 results